Objectives:

- Describe how UK Neurosurgery is organized for inpatient care

- Distinguish neurosurgery emergencies from non-emergent pathologies

- Outline resources for effective collaboration with UK Neurosurgery

Financial Disclosure Summary

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

Justin Fraser, MD, FAANS, FAHA, FCNS speaker for this session, has a financial relationship (Professional Services) with the following: NIH UL1TR000117, AHA, Fawkes Biotechnology, Stream Biotechnology, Cerelux, LLC, LaFeBelle, LLC, LETSGETPROOF, Medtronic, Penumbra, Imperative Care, Stryker, Viz.ai, and Novartis.

All of the relevant financial relationships listed for these individuals have been mitigated. No other speakers, authors, planners or content reviewers have any relevant financial relationship to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.